secwatch.observer — SEC 8-K summary
======================================

Issuer:     Incannex Healthcare Inc. (IXHL)
CIK:        0001873875
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001213900-26-009160
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incannex Healthcare Appoints Three New Members to Clinical Advisory Board for PSX-001 Program
--------------------------------------------------------------------------------

- Appointed Murray B. Stein, MD, MPH (UCSD); Andrew Cutler, MD (SUNY Upstate); and Amir Kalali, MD to Clinical Advisory Board.
- Drs. Stein, Cutler, and Kalali bring expertise in psychiatry, neurobiology, psychopharmacology, and clinical development.
- CAB will advise on PSX-001 clinical trial design, endpoint selection, regulatory engagement, and development strategy.
- CMO Dr. Lou Barbato stated the appointments support disciplined execution and risk management for PSX-001 program.
- Incannex Healthcare (IXHL) is a Nasdaq-listed clinical-stage biopharma developing innovative combination therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026009160/0001213900-26-009160-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1873875/000121390026009160/ea0274539-8k_incannex.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-009160

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer